On the other hand, intraperitoneal or subconjunctival treatments of mice with anti-Gal-9 antibodies do not affect the severity of pollen-induced allergic conjunctivitis, both in the induction and effector phases of the disease [33]. This evidence concerns the gene LGALS9 and atopic conjunctivitis.